|
|
Article: Anti-Alzheimer's Disease Drugs (Cholinesterase Inhibitors, and NMDARA), and Anti-Parkinson's Disease Drugs (Dopaminergic Agents, and Dopamine Agonists) are Classified inside 2006 Global Strategic Business Report.
- Article from:
- Business Wire
- Article date:
- November 27, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c45944) has announced the addition of Alzheimers and Parkinsons Disease - Global Strategic Business Report to their offering.
This report analyzes the worldwide markets for Alzheimer's and Parkinson's Disease in Millions of US$. The Major product classes Analyzed are Anti-Alzheimer's Disease Drugs (Cholinesterase Inhibitors, and NMDARA), and Anti-Parkinson's Disease Drugs (Dopaminergic Agents, and Dopamine Agonists). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the ...